{"id":"NCT01569295","sponsor":"Gilead Sciences","briefTitle":"Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-06-15","primaryCompletion":"2019-06-10","completion":"2019-06-10","firstPosted":"2012-04-03","resultsPosted":"2018-02-27","lastUpdate":"2020-03-10"},"enrollment":416,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Lymphocytic Leukemia"],"interventions":[{"type":"DRUG","name":"Idelalisib","otherNames":["GS-1101","CAL-101","Zydelig速"]},{"type":"DRUG","name":"Rituximab","otherNames":["Rituxan速","MabThera"]},{"type":"DRUG","name":"Bendamustine","otherNames":["Ribomustin","Treanda速"]},{"type":"DRUG","name":"Placebo to match idelalisib","otherNames":[]}],"arms":[{"label":"Idelalisib+bendamustine+rituximab","type":"EXPERIMENTAL"},{"label":"Placebo to match idelalisib+bendamustine+rituximab","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study is to evaluate the effect of the addition of idelalisib (formerly GS-1101) to bendamustine + rituximab (BR) on progression-free survival (PFS) in participants with previously treated chronic lymphocytic leukemia (CLL)","primaryOutcome":{"measure":"Progression-Free Survival (PFS)","timeFrame":"Up to 84 months","effectByArm":[{"arm":"Idelalisib + Bendamustine + Rituximab","deltaMin":21.8,"sd":null},{"arm":"Placebo + Bendamustine + Rituximab","deltaMin":11.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":106,"countries":["United States","Australia","Belgium","Canada","Croatia","Czechia","France","Greece","Hungary","Ireland","Italy","Poland","Portugal","Romania","Russia","Spain","Turkey (T端rkiye)","United Kingdom"]},"refs":{"pmids":["28139405","31729982"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":152,"n":207},"commonTop":["Neutropenia","Diarrhoea","Pyrexia","Nausea","Anaemia"]}}